The start of 2020 was marked by the renewal of its shareholding structure with new long-term partners investing alongside management and historic minority investors with the aim of ensuring the continued independent development of the group.

In 2019, Ceva posted growth of 14.6 percent (AER) on the previous year (10.4 percent CER), with sales of more than €1.2 billion. In 20 years, the French-based multinational has multiplied its sales by 10. Today, the group is directly present in 46 countries, and recorded positive growth in all geographical zones: Europe +14 percent, Africa/Middle East/Eastern Europe/Turkey/Russia +17 percent, North America /Pacific +21 percent, Latin America +24 percent and Asia +3 percent.

All species grew, with the strongest performance in poultry (+22 percent), followed by swine (+13 percent), companion animals (+9 percent) and ruminants (+7 percent).

New Ambition 2025 plan: focuses on a virtuous circle of growth to double sales

Ceva recently concluded its 5th finance round with 4 new strategic investors (Téthys Inves - France, PSP - Canada, Mitsui - Japan, Klocke Gruppe - Germany) investing alongside management. This round of financing will give the group all the resources it requires to continue its exponential growth and double sales by 2025.

Continued investment in R&D and industrial centres

The group invested close to 11 percent of its sales in R&D during 2019, as it gets closer to its stated objective of achieving a 50:50 split between vaccine and pharmaceutical sales. To achieve this, it also invests over €100 million each year in its industrial facilities around the world. Some of the highlights during 2019 included:

• The completion of a Global centre for innovation of companion animal products at the Ceva Laval Campus, France.
• The creation near Angers, France of the first reference site in Europe for the design and manufacture of veterinary autovaccines (inauguration H1 2020)
• The development of a new Global Innovation Centre for swine vaccines in Dessau, Germany

“This year we invested nearly 11 percent of our sales revenues in R&D to support our innovation strategy. We completed the construction of the Ceva Laval Campus, our new global innovation centre for companion animals based in Laval, France, all of which give us a strong base as we enter our new Ambition 2025 strategic plan”, commented Dr. Marc Prikazsky, President & CEO of Ceva. “Another key event that marked 2019 was the acquisition of the veterinary activities of IDT Biologika in Germany which has allowed us to strengthen our expertise and R&D in swine vaccines. I'm delighted how quickly the new campus in Dessau has become part of Ceva.”

Royalty-free visuals available by clicking HERE

Corporate Press Pack available by clicking HERE